Arachidonic acid and its COX1/2 metabolites inhibit interferon-γ mediated induction of indoleamine-2,3 dioxygenase in THP-1 cells and Human monocytes

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 87, Issue 4-5, 2012, Pages 119-126

  Bassal, Nesrine Kamal ^a   Hughes, Bernard P ^a   Costabile, Maurizio ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Arachidonic acid; Cancer; Fatty acids; Indoleamine dioxygenase; Prostaglandins

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; MESSENGER RNA; PROSTAGLANDIN A2; PROSTAGLANDIN D2; PROSTAGLANDIN E2; STAT1 PROTEIN;

ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REGULATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INDOLEAMINE 2,3 DIOXYGENASE GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ARACHIDONIC ACID; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENZYME INDUCTION; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INDOMETHACIN; INTERFERON-GAMMA; MONOCYTES; NITROBENZENES; NORDIHYDROGUAIARETIC ACID; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; STAT1 TRANSCRIPTION FACTOR; SULFONAMIDES;

EID: 84867231174     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2012.08.001     Document Type: Article

References (45)

1. Takikawa O., Kuroiwa T., Yamazaki F., Kido R. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J. Biol. Chem. 1988, 263:2041-2048.
2. Werner-Felmayer G., Werner E.R., Fuchs D., Hausen A., Reibnegger G., Wachter H. Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim. Biophys. Acta 1989, 1012:140-147.
3. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5:375-386.
4. Hissong B.D., Byrne G.I., Padilla M.L., Carlin J.M. Upregulation of interferon-induced indoleamine 2,3-dioxygenase in human macrophage cultures by lipopolysaccharide, muramyl tripeptide, and interleukin-1. Cell. Immunol. 1995, 160:264-269.
5. Currier A.R., Ziegler M.H., Riley M.M, Babcock T.A., Telbis V.P., Carlin J.M. Tumor necrosis factor-alpha and lipopolysaccharide enhance interferon-induced antichlamydial indoleamine dioxygenase activity independently. J. Interf. Cytok. Res. 2000, 20:369-376.
6. Musso T., Gusella G.L., Brooks A., Longo D.L., Varesio L. Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood 1994, 83:1408-1411.
7. Leslie M. Immunology. Fetal immune system hushes attacks on maternal cells. Science 2008, 322:1450-1451.
8. Brown R.R., Ozaki Y., Datta S.P., Borden E.C., Sondel P.M., Malone D.G. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv. Exp. Med. Biol. 1991, 294:425-435.
9. Munn D.H., Mellor A.L Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 2007, 117:1147-1154.
10. Uyttenhove C., Pilotte L., Theate I., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9:1269-1274.
11. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., Ferrara G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 2002, 196:459-468.
12. Terness P., Bauer T.M., Rose L., et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 2002, 196:447-457.
13. Munn D.H., Sharma M.D., Baban B., et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005, 22:633-642.
14. Dong J., Qiu H., Garcia-Barrio M., Anderson J., Hinnebusch A.G. Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. Mol. Cell 2000, 6:269-279.
15. Okamoto A., Nikaido T., Ochiai K., et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 2005, 11:6030-6039.
16. Ino K., Yoshida N., Kajiyama H., et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Brit. J. Cancer 2006, 95:1555-1561.
17. Brandacher G., Perathoner A., Ladurner R., et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 2006, 12:1144-1451.
18. Riediger N.D., Othman R.A., Suh M., Moghadasian M.H. A systemic review of the roles of n-3 fatty acids in health and disease. J. Am. Diet. Assoc. 2009, 109:668-679.
19. Cohen L.A. Lipids in cancer: an introduction. Lipids 1992, 27:791-792.
20. Costabile M., Hii C.S., Robinson B.S., et al. A novel long chain polyunsaturated fatty acid, beta-Oxa 21:3n-3, inhibits T lymphocyte proliferation, cytokine production, delayed-type hypersensitivity, and carrageenan-induced paw reaction and selectively targets intracellular signals. J. Immunol. 2001, 167:3980-3987.
21. Laich A., Neurauter G., Widner B., Fuchs D. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin. Chem. 2002, 48:579-581.
22. Matsunaga A., Kawamoto M., Shiraishi S., et al. Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats. Eur. J. Pharmacol. 2007, 554:12-17.
23. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
24. Heimberg M., Dunn G.D., Wilcox G. The derivation of plasma-free fatty acids from dietary neutral fat in man. J. Lab. Clin. Med. 1974, 83:393-402.
25. Winkler J.D., Sung C.M., Hubbard W.C., Chilton F.H. Influence of arachidonic acid on indices of phospholipase A2 activity in the human neutrophil. Biochem. J. 1993, 291:825-831.
26. 2+ mobilization by arachidonic acid. Comparison with myo-inositol 1,4,5-trisphosphate in isolated pancreatic islets. J. Biol. Chem. 1986, 261:3501-3511.
27. Costabile M., Hii C.S., Melino M., Easton C., Ferrante A. The immunomodulatory effects of novel beta-oxa, beta-thia, and gamma-thia polyunsaturated fatty acids on human T lymphocyte proliferation, cytokine production, and activation of protein kinase C and MAPKs. J. Immunol. 2005, 174:233-243.
28. Sotero-Esteva W.D., Wolfe D., Ferris M., Taylor M.W. An indoleamine 2,3-dioxygenase-negative mutant is defective in STAT1 DNA binding: differential response to IFN-gamma and IFN-alpha. J. Interf. Cytok. Res. 2000, 20:623-632.
29. Johnson B.A., Baban B., Mellor A.L. Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy 2009, 1:645-661.
30. Prendergast G.C., Chang M.Y., Mandik-Nayak L., Metz R., Muller A.J. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr. Med. Chem. 2011, 18:2257-2262.
31. Schroecksnadel K., Zangerle R., Bellmann-Weiler R., Garimorth K., Weiss G., Fuchs D. Indoleamine-2, 3-dioxygenase and other interferon-gamma-mediated pathways in patients with human immunodeficiency virus infection. Curr. Drug Metab. 2007, 8:225-236.
32. Fallarino F., Grohmann U., Vacca C., et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002, 9:1069-1077.
33. Masferrer J.L., Zweifel B.S., Manning P.T., et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA 1994, 9:3228-3232.
34. Fang C., Jiang Z., Tomlinson D.R. Expression of constitutive cyclo-oxygenase (COX-1) in rats with streptozotocin-induced diabetes; effects of treatment with evening primrose oil or an aldose reductase inhibitor on COX-1 mRNA levels. Prostagl. Leukotr. Ess. Fatty Acids 1997, 56:157-163.
35. Smith C.J., Morrow J.D., Roberts L.J., Marnett L.J. Differentiation of monocytoid THP-1 cells with phorbol ester induces expression of prostaglandin endoperoxide synthase-1 (COX-1). Biochem. Biophys. Res. Commun. 1993, 192:787-793.
36. Braun D., Longman R.S., Albert M.L. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005, 106:2375-2381.
37. Jung I.D., Jeong Y.I., Lee C.M., Noh K.T., Jeong S.K., Chun S.H., Choi OH, Park W.S., Han J., Shin Y.K., Kim H.W., Yun C.H., Park Y.M. COX-2 and PGE2 signaling is essential for the regulation of IDO expression by curcumin in murine bone marrow-derived dendritic cells. Int. Immunopharmacol. 2010, 10:760-768.
38. Bates E.J., Ferrante A., Smithers L., Poulos A., Robinson B.S. Effect of fatty acid structure on neutrophil adhesion, degranulation and damage to endothelial cells. Atherosclerosis 1995, 116:247-259.
39. Van Nieuwenhoven F.A., Van der Vusse G.J., Glatz J.F. Membrane-associated and cytoplasmic fatty acid-binding proteins. Lipids 1996, 31:223-227.
40. Hii C.S., Ferrante A., Edwards Y.S., et al. Activation of mitogen-activated protein kinase by arachidonic acid in rat liver epithelial WB cells by a protein kinase C-dependent mechanism. J. Biol. Chem. 1995, 270:4201-4204.
41. Wen Z., Zhong Z., Darnell J.E. Maximal activation of transcription by STAT1 and STAT3 requires both tyrosine and serine phosphorylation. Cell 1995, 82:241-250.
42. 12,14-prostaglandin J2 inhibits INF-γ-induced JAK/STAT1 signalling pathway activation and IP-10/CXCL10 expression in mesangial cells. Nephrol. Dial. Transpl. 2008, 23:3776-3785.
43. 2 and rosiglitazone suppress Janus kinase-STAT inflammatory signalling through induction of suppressor or cytokine signalling 1 (SOCS1) and SOCS3 in glia. J. Biol. Chem. 2003, 278:14747-14752.
44. Jiang G.M., He Y.W., Fang R., Zhang G., Zeng J., Yi Y.M., Zhang S., Bu X.Z., Cai S.H., Du J. Sodium butyrate down-regulation of indoleamine 2,3-dioxygenase at the transcriptional and post-transcriptional levels. Int. J. Biochem. Cell. Biol. 2010, 42:1840-1846.
45. Calder P.C. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 2009, 91:791-795.